Global Pemphigus Vulgaris Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2024 –2030 |
 Taille du marché (année de référence) |
|
 Taille du marché (année de prévision) |
Dollars américains 677.32 |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché mondial du pemphigus vulgaire, par diagnostic et traitement (diagnostic et traitement), type de population (pédiatrique, adulte et gériatrique), utilisateur final (hôpitaux, cliniques spécialisées, instituts de recherche et autres), canal de distribution (pharmacie d'hôpitaux, pharmacie de détail et pharmacie en ligne) - Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et perspectives du marché du pemphigus vulgaire
L'utilisation et l'adoption croissantes des technologies de santé numériques ont renforcé la demande du marché. Les principaux acteurs du marché se concentrent sur l'approbation et la disponibilité de divers produits au cours de cette période cruciale. En outre, l'augmentation du nombre d'établissements de santé améliorés et avancés contribue également à la demande croissante du marché.
Le marché devrait croître au cours de l'année de prévision en raison de l'augmentation des troubles cutanés d'origine immunitaire. Le soutien apporté aux patients atteints de pemphigus vulgaire par diverses ONG devrait également stimuler la croissance du marché. Parallèlement à cela, les fabricants sont engagés dans des activités de R&D et d'approbation sur le marché. Cependant, les directives réglementaires strictes associées aux procédures de traitement et aux approbations de médicaments devraient freiner la croissance du marché. La demande croissante de médecine personnalisée devrait offrir des opportunités au marché. La demande croissante de soins de santé de meilleure qualité avec toutes les installations devrait stimuler la croissance du marché. Cependant, les effets indésirables associés au traitement devraient remettre en cause la croissance du marché.
Data Bridge Market Research analyse que le marché mondial du pemphigus vulgaire devrait atteindre une valeur de 677,32 millions USD d'ici 2030, à un TCAC de 8,2 % au cours de la période de prévision. Le diagnostic et le traitement représentent le segment de type le plus important du marché en raison du nombre croissant de patients atteints de pemphigus vulgaire au sein de la population mondiale. Ce rapport de marché couvre également en profondeur l'analyse des prix, l'analyse des brevets et les avancées technologiques.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable de 2015 à 2020) |
|
Unités quantitatives |
Chiffre d'affaires en millions, volumes en unités et prix en USD |
|
Segments couverts |
Diagnostic et traitement (diagnostic et traitement), type de population (pédiatrie, adultes et gériatrie), utilisateur final (hôpitaux, cliniques spécialisées, instituts de recherche et autres), canal de distribution (pharmacie d'hôpitaux, pharmacie de détail et pharmacie en ligne) |
|
Pays couverts |
États-Unis, Canada et Mexique, Allemagne, France, Royaume-Uni, Italie, Russie, Espagne, Pays-Bas, Suisse, Belgique, Turquie et reste de l'Europe, Chine, Japon, Inde, Australie, Corée du Sud, Singapour, Malaisie, Thaïlande, Indonésie, Philippines et reste de l'Asie-Pacifique, Afrique du Sud, Arabie saoudite, Émirats arabes unis, Israël, Égypte et reste du Moyen-Orient et de l'Afrique, Brésil, Argentine et reste de l'Amérique du Sud |
|
Acteurs du marché couverts |
Sanofi, Regeneron Pharmaceuticals Inc., Fresenius Kabi AG, Boehringer Ingelheim International GmbH, Johnson & Johnson Services, Inc., RAKSHIT DRUGS PVT. LTD, F. Hoffmann-La Roche Ltd, Pfizer Inc., Celltrion Healthcare Co., Ltd., AbbVie Inc., Novartis AG, Amgen Inc., Merck & Co., Inc., AstraZeneca, Teva Pharmaceutical Industries Ltd, Lilly, Zydus Group et GSK plc, entre autres. |
Définition du marché mondial du pemphigus vulgaire
Une maladie auto-immune chronique rare appelée pemphigus vulgaire se caractérise par le développement de cloques sur la peau et les muqueuses. On pense qu'il s'agit de la variante la plus courante de la maladie auto-immune bulleuse connue sous le nom de pemphigus. Dans le cas du pemphigus vulgaire, le système immunitaire génère involontairement des anticorps qui ciblent les desmogléines, une classe de protéines nécessaires à la fixation des cellules cutanées. Des cloques se développent en raison de cette attaque d'anticorps et les couches cutanées se séparent. Le corps peut développer des cloques n'importe où, mais la bouche, la gorge, le cuir chevelu, le visage, la poitrine, l'aine et les aisselles sont les endroits les plus courants où elles apparaissent. La sensibilisation croissante aux maladies devrait stimuler la croissance du marché.
Bien que l’origine précise du pemphigus vulgaire soit inconnue, on pense qu’il résulte d’une confluence de prédisposition génétique et de stimuli environnementaux. Chez les personnes sensibles, certains facteurs, comme des médicaments spécifiques, des infections ou une exposition aux rayons UV, peuvent provoquer la maladie ou l’aggraver. Cependant, des directives réglementaires strictes devraient freiner la croissance du marché.
Dynamique du marché mondial du pemphigus vulgaire
Cette section traite de la compréhension des moteurs, des opportunités, des contraintes et des défis du marché. Tout cela est discuté en détail ci-dessous :
Conducteurs
- Nouvelles options de traitement pour le pemphigus vulgaire
Le pemphigus vulgaire est un trouble chronique du système immunitaire qui touche un faible pourcentage de personnes. Il se manifeste par l'apparition de cloques sur la peau et dans la bouche. Des médicaments peuvent toutefois aider à le contrôler s'il est grave. Les auto-anticorps qui ciblent les molécules d'adhésion entre les kératinocytes provoquent une maladie bulleuse auto-immune persistante et grave appelée pemphigus. Cette maladie doit être prise en charge pendant deux à trois ans en moyenne.
Le traitement par glucocorticoïdes systémiques peut sauver des vies chez les personnes atteintes de pemphigus vulgaire, mais il peut aussi avoir des effets secondaires mortels. Avant qu'il ne soit nécessaire d'administrer des glucocorticoïdes systémiques, un patient atteint de pemphigus vulgaire et de myasthénie grave a été traité pendant près de cinq ans avec des médicaments cholinomimétiques comme le Mestinon (bromure de pyridostigmine), l'Imuran (azathioprine) et un gel corticostéroïde topique.
Ainsi, les nouvelles options ou approches de traitement du pemphigus vulgaire devraient stimuler la croissance du marché.
- Le soutien croissant des ONG aux patients concernés
De nombreuses organisations non gouvernementales (ONG) et groupes de soutien aux patients déploient de nombreux efforts pour aider les personnes atteintes de pemphigus vulgaire en leur proposant assistance, ressources et plaidoyer. Des organisations de soutien locales ou régionales axées sur le pemphigus vulgaire peuvent exister dans des régions ou des pays particuliers. Ces organisations peuvent proposer des activités de plaidoyer spécifiques à la communauté, une assistance par les pairs et des ressources locales.
Ainsi, le soutien croissant des ONG aux patients souffrant de pemphigus vulgaire devrait stimuler la croissance du marché.
Opportunité
- Technologies de santé numériques pour la gestion des traitements
Les technologies de santé numériques ont le potentiel d’avoir une influence significative sur le traitement et la gestion des patients atteints de pemphigus vulgaire. Les dermatologues et autres professionnels de la santé peuvent être consultés virtuellement par les patients grâce à la télémédecine, éliminant ainsi le besoin de rendez-vous en personne. Cela peut être particulièrement utile pour les personnes atteintes de pemphigus vulgaire qui peuvent avoir du mal à se rendre dans les établissements médicaux en raison de problèmes de mobilité ou d’un accès restreint. Les examens réguliers, le suivi des médicaments et les rendez-vous de suivi peuvent être facilités grâce à la télémédecine, ce qui permet une continuité des soins et des modifications immédiates des programmes de traitement.
De nombreuses applications mobiles et outils en ligne peuvent être des ressources utiles pour les patients atteints de pemphigus vulgaire. Ces plateformes peuvent proposer des outils d'autosurveillance, des rappels de médicaments et des ressources pédagogiques. Les patients peuvent suivre leurs symptômes, leurs médicaments et l'évolution de la maladie, ce qui leur permet de participer activement à leurs propres soins et d'interagir plus efficacement avec les professionnels de la santé. De nombreuses cliniques et organisations de soins de santé proposent des tests immunologiques et des analyses sanguines aux patients via leurs portails Web, ce qui simplifie la tâche à ceux qui rencontrent des difficultés en raison de diverses circonstances, notamment un accès limité aux laboratoires de pathologie et autres.
Ainsi, les solutions de santé numérique ou les technologies de gestion des traitements devraient constituer une opportunité de croissance du marché.
Défis/ Restrictions
- Effets indésirables associés aux médicaments
Les médicaments qui inhibent le système immunitaire sont utilisés pour traiter le pemphigus vulgaire (PV) afin de gérer la réaction auto-immune. Bien que ces médicaments puissent aider à gérer le PV, ils peuvent également avoir des effets secondaires nocifs. Selon le médicament et la personne, les effets secondaires précis peuvent varier. Le traitement de chaque patient doit être personnalisé en fonction de ses antécédents médicaux et de ses troubles comorbides. Tout en recevant les meilleurs soins possibles, les patients peuvent souffrir d'une activité minimale de la maladie. Les médicaments conçus pour prévenir la formation de cloques sont généralement utilisés en première intention. Ils fonctionnent généralement mieux au stade initial.
Ainsi, les effets indésirables liés aux médicaments devraient constituer un obstacle à la croissance du marché.
- Des directives réglementaires strictes
The provision of advice and standards for the diagnosis, treatment, and management of numerous medical disorders, including pemphigus vulgaris, is facilitated by regulatory guidelines. Regulatory agencies and organizations focusing on dermatological or autoimmune illnesses usually establish these guidelines. To ensure the safety, effectiveness, and quality of drugs used to treat pemphigus vulgaris, regulatory agencies may assess and approve them.
To make educated choices about the authorization and supervision of pharmaceuticals, they may consider information from clinical trials, manufacturing procedures, and adverse event reporting systems.
Thus, strict regulatory guidelines are expected to restrain the market growth.
Recent Developments
- In June 2023, AstraZeneca announced that for the treatment of adult patients with refractory generalized myasthenia gravis (gMG) and anti-acetylcholine receptor (AChR) antibody positivity, Soliris (eculizumab) had received approval in China. The only complement inhibitor authorized for the treatment of gMG in China is Soliris. Comprehensive findings from the Phase III REGAIN trial served as the foundation for the clearance by the National Medical Products Administration (NMPA) in China.
- In January 2023, Merck & Co., Inc. announced the FDA has approved KEYTRUDA, Merck's anti-PD-1 therapy, as a single agent for adjuvant therapy following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a 4 centimetres [cm]), II, or IIIA non-small cell lung cancer (NSCLC).
Global Pemphigus Vulgaris Market Scope
The global pemphigus vulgaris market is segmented into diagnosis and treatment, population type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of development and strategies to approach the market and determine your core application areas and the difference in your target markets.
Diagnosis and Treatment
- Diagnosis
- Treatment
On the basis of diagnosis and treatment, the market is segmented into diagnosis and treatment.
Population Type
- Pediatric
- Adults
- Geriatric
On the basis of population type, the market is segmented into pediatric, adults, and geriatric.
End User
- Hospitals
- Specialty Clinics
- Research Institutes
- Others
On the basis of end user, the market is segmented into hospitals, specialty clinics, research institutes, and others.
Distribution Channel
- Hospitals Pharmacy
- Retail Pharmacy
- Online Pharmacy
On the basis of distribution channel, the market is segmented into hospitals pharmacy, retail pharmacy, and online pharmacy.
Global Pemphigus Vulgaris Market Regional Analysis/Insights
The market is analyzed, and market size information is provided by diagnosis and treatment, population type, end user, and distribution channel.
The countries covered in this market report are U.S., Canada, and Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, and Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, and Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Israel, Egypt, and Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.
North America is expected to dominate due to the presence of key market players in the largest consumer market with high GDP. The U.S. is expected to grow due to the rise in technological advancement for pemphigus vulgaris.
The increasing investment in R&D and increasing adoption of personalized medicine for pemphigus vulgaris as an option for the formulation of treatment regimens are expected to boost the market growth. The U.S. dominates the North American region due to the strong presence of advanced technology providers such as Novartis AG, Amgen Inc., Merck & Co., Inc., AstraZeneca, and others. The Germany dominates the Europe region due to the increasing demand from emerging markets and the expansion of healthcare industries. China dominates the Asia-Pacific region due to an increase in healthcare expenditure.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Pemphigus Vulgaris Market Share Analysis
Global pemphigus vulgaris market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the global pemphigus vulgaris market.
Français Certains des principaux acteurs opérant sur le marché mondial du pemphigus vulgaire sont Sanofi, Regeneron Pharmaceuticals Inc., Fresenius Kabi AG, Boehringer Ingelheim International GmbH, Johnson & Johnson Services, Inc., RAKSHIT DRUGS PVT. LTD, F. Hoffmann-La Roche Ltd, Pfizer Inc., Celltrion Healthcare Co., Ltd., AbbVie Inc., Novartis AG, Amgen Inc., Merck & Co., Inc., AstraZeneca, Teva Pharmaceutical Industries Ltd, Lilly, Zydus Group, GSK plc., entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER FIVE FORCES
4.3 PATENT ANALYSIS
4.4 PATIENT FLOW DIAGRAM
4.5 KEY PRICING STRATEGIES
4.6 FUTURE THERAPIES
4.7 KEY PATIENT ENROLLMENT STRATEGIES
5 PIPELINE ANALYSIS
6 EPIDEMIOLOGY
7 INDUSTRY INSIGHTS
8 GLOBAL PEMPHIGUS VULGARIS MARKET: REGULATIONS
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS
9.1.2 GROWING SUPPORT OF NGOS FOR THE AFFECTED PATIENTS
9.1.3 AWARENESS REGARDING THE DISEASE
9.2 RESTRAINTS
9.2.1 STRICT REGULATORY GUIDELINES
9.2.2 HIGH TREATMENT COSTS
9.3 OPPORTUNITIES
9.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE
9.3.2 INCREASING HEALTHCARE FACILITIES
9.3.3 DIGITAL HEALTH TECHNOLOGIES FOR TREATMENT MANAGEMENT
9.4 CHALLENGES
9.4.1 ADVERSE EFFECTS ASSOCIATED WITH MEDICATIONS
9.4.2 REIMBURSEMENT AND COVERAGE POLICIES
10 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT
10.1 OVERVIEW
10.2 TREATMENT
10.2.1 MEDICATIONS, BY TYPE
10.2.1.1 CORTICOSTEROIDS
10.2.1.2 STEROID- SPARING IMMUNOSUPPRESSANT DRUGS
10.2.1.2.1 AZATHIOPRINE
10.2.1.2.2 MYCOPHENALATE MOFETIL
10.2.1.2.3 METHOTREXATE
10.2.1.2.4 CYCLOPHOSPHAMIDE
10.2.1.2.5 MIZORIBINE
10.2.1.2.6 OTHERS
10.2.1.3 ANTI- INFLAMMATORY AGENTS
10.2.1.3.1 DIAMINODYPHENYL SULFONE
10.2.1.3.2 TETRACYCLINE
10.2.1.3.3 OTHERS
10.2.1.4 BIOLOGICS
10.2.1.5 INTRAVENOUS IMMUNOGLOBULIN
10.2.1.6 ANTIBIOTICS
10.2.1.7 ANTIFUNGALS
10.2.1.8 ANTIVIRALS
10.2.1.9 OTHER MEDICATIONS
10.2.2 MEDICATIONS, BY ROUTE OF ADMINISTRATION
10.2.2.1 ORAL
10.2.2.2 TOPICAL
10.2.2.3 PARENTERAL
10.2.2.4 OTHERS
10.2.3 MEDICATIONS, BY DRUG TYPE
10.2.3.1 GENERIC
10.2.3.2 BRANDED
10.3 DIAGNOSIS
10.3.1 SKIN BIOPSY
10.3.2 BLOOD TEST
10.3.3 ENDOSCOPY
11 GLOBAL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE
11.1 OVERVIEW
11.2 ADULTS
11.3 GERIATRIC
11.4 PEDIATRIC
12 GLOBAL PEMPHIGUS VULGARIS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 SPECIALTY CLINICS
12.4 RESEARCH INSTITUTES
12.5 OTHERS
13 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 HOSPITALS PHARMACY
13.3 RETAIL PHARMACY
13.4 ONLINE PHARMACY
14 GLOBAL PEMPHIGUS VULGARIS MARKET, BY REGION
14.1 OVERVIEW
14.2 NORTH AMERICA
14.2.1 U.S.
14.2.2 CANADA
14.2.3 MEXICO
14.3 EUROPE
14.3.1 GERMANY
14.3.2 U.K.
14.3.3 FRANCE
14.3.4 ITALY
14.3.5 SPAIN
14.3.6 SWITZERLAND
14.3.7 TURKEY
14.3.8 RUSSIA
14.3.9 BELGIUM
14.3.10 NETHERLANDS
14.3.11 REST OF EUROPE
14.4 ASIA-PACIFIC
14.4.1 CHINA
14.4.2 INDIA
14.4.3 SOUTH KOREA
14.4.4 MALAYSIA
14.4.5 JAPAN
14.4.6 AUSTRALIA
14.4.7 SINGAPORE
14.4.8 THAILAND
14.4.9 INDONESIA
14.4.10 PHILIPPINES
14.4.11 REST OF ASIA-PACIFIC
14.5 SOUTH AMERICA
14.5.1 BRAZIL
14.5.2 ARGENTINA
14.5.3 REST OF SOUTH AMERICA
14.6 MIDDLE EAST AND AFRICA
14.6.1 SAUDI ARABIA
14.6.2 EGYPT
14.6.3 U.A.E.
14.6.4 SOUTH AFRICA
14.6.5 ISRAEL
14.6.6 REST OF MIDDLE EAST AND AFRICA
15 GLOBAL PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 ABBVIE INC.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 MERCK & CO., INC.,
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 SANOFI
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 REGENERON PHARMACEUTICALS INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 NOVARTIS AG
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 AMGEN INC.
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENTS
17.7 ASTRAZENECA
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 COMPANY SHARE ANALYSIS
17.7.4 PRODUCT PORTFOLIO
17.7.5 RECENT DEVELOPMENTS
17.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 CELLTRION HEALTHCARE CO., LTD
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENTS
17.1 F. HOFFMANN- LA ROCHE LTD.
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 FRESENIUS KABI AG
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.12 GSK PLC
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENT
17.13 JOHNSON & JOHNSON SERVICES, INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 COMPANY SHARE ANALYSIS
17.13.4 PRODUCT PORTFOLIO
17.13.5 RECENT DEVELOPMENT
17.14 LILLY
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENT
17.15 PFIZER INC.
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENT
17.16 RAKSHIT DRUGS PVT. LTD
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.17 TEVA PHARMACEUTICAL INDUSTRIES LTD
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PRODUCT PORTFOLIO
17.17.4 RECENT DEVELOPMENT
17.18 ZYDUS GROUP
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
Liste des tableaux
TABLE 1 GLOBAL PEMPHIGUS VULGARIS MARKET, PATENT ANALYSIS
TABLE 2 GLOBAL PEMPHIGUS VULGARIS MARKET, PIPELINE ANALYSIS
TABLE 3 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 4 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 6 GLOBAL STEROID- SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 7 GLOBAL ANTI- INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 8 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 9 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 10 GLOBAL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 GLOBAL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 12 GLOBAL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 13 GLOBAL ADULTS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 GLOBAL GERIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 GLOBAL PEDIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 GLOBAL PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 17 GLOBAL HOSPITALS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 GLOBAL SPECIALTY CLINICS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 GLOBAL RESEARCH INSTITUTES IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 GLOBAL OTHERS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 22 GLOBAL HOSPITALS PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 GLOBAL RETAIL PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 GLOBAL ONLINE PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 GLOBAL PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 37 U.S. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 38 U.S. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 39 U.S. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 40 U.S. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 41 U.S. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 42 U.S. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 43 U.S. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 44 U.S. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 45 U.S. PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 46 U.S. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 47 CANADA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 48 CANADA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 49 CANADA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 50 CANADA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 51 CANADA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 52 CANADA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 53 CANADA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 54 CANADA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 55 CANADA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 56 CANADA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 57 MEXICO PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 58 MEXICO TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 59 MEXICO STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 60 MEXICO ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 61 MEXICO TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 62 MEXICO TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 63 MEXICO DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 64 MEXICO PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 65 MEXICO PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 66 MEXICO PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 67 EUROPE PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 68 EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 69 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 70 EUROPE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 71 EUROPE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 72 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 73 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 74 EUROPE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 75 EUROPE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 76 EUROPE PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 77 EUROPE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 78 GERMANY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 79 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 80 GERMANY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 81 GERMANY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 82 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 83 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 84 GERMANY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 85 GERMANY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 86 GERMANY PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 87 GERMANY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 88 U.K. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 89 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 90 U.K. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 91 U.K. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 92 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 93 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 94 U.K. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 95 U.K. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 96 U.K. PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 97 U.K. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 98 FRANCE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 99 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 100 FRANCE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 101 FRANCE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 102 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 103 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 104 FRANCE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 105 FRANCE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 106 FRANCE PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 107 FRANCE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 108 ITALY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 109 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 110 ITALY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 111 ITALY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 112 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 113 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 114 ITALY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 115 ITALY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 116 ITALY PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 117 ITALY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 118 SPAIN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 119 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 120 SPAIN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 121 SPAIN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 122 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 123 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 124 SPAIN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 125 SPAIN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 126 SPAIN PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 127 SPAIN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 128 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 129 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 130 SWITZERLAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 131 SWITZERLAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 132 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 133 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 134 SWITZERLAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 135 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 136 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 137 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 138 TURKEY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 139 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 140 TURKEY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 141 TURKEY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 142 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 143 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 144 TURKEY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 145 TURKEY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 146 TURKEY PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 147 TURKEY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 148 RUSSIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 149 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 150 RUSSIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 151 RUSSIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 152 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 153 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 154 RUSSIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 155 RUSSIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 156 RUSSIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 157 RUSSIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 158 BELGIUM PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 159 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 160 BELGIUM STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 161 BELGIUM ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 162 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 163 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 164 BELGIUM DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 165 BELGIUM PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 166 BELGIUM PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 167 BELGIUM PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 168 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 169 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 170 NETHERLANDS STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 171 NETHERLANDS ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 172 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 173 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 174 NETHERLANDS DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 175 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 176 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 177 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 178 REST OF EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 179 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 180 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 181 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 182 ASIA-PACIFIC STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 183 ASIA-PACIFIC ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 184 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 185 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 186 ASIA-PACIFIC DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 187 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 188 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 189 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 190 CHINA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 191 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 192 CHINA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 193 CHINA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 194 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 195 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 196 CHINA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 197 CHINA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 198 CHINA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 199 CHINA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 200 INDIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 201 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 202 INDIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 203 INDIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 204 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 205 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 206 INDIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 207 INDIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 208 INDIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 209 INDIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 210 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 211 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 212 SOUTH KOREA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 213 SOUTH KOREA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 214 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 215 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 216 SOUTH KOREA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 217 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 218 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 219 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 220 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 221 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 222 MALAYSIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 223 MALAYSIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 224 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 225 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 226 MALAYSIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 227 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 228 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 229 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 230 JAPAN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 231 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 232 JAPAN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 233 JAPAN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 234 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 235 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 236 JAPAN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 237 JAPAN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 238 JAPAN PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 239 JAPAN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 240 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 241 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 242 AUSTRALIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 243 AUSTRALIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 244 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 245 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 246 AUSTRALIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 247 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 248 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 249 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 250 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 251 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 252 SINGAPORE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 253 SINGAPORE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 254 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 255 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 256 SINGAPORE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 257 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 258 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 259 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 260 THAILAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 261 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 262 THAILAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 263 THAILAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 264 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 265 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 266 THAILAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 267 THAILAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 268 THAILAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 269 THAILAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 270 INDONESIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 271 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 272 INDONESIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 273 INDONESIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 274 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 275 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 276 INDONESIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 277 INDONESIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 278 INDONESIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 279 INDONESIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 280 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 281 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 282 PHILIPPINES STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 283 PHILIPPINES ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 284 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 285 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 286 PHILIPPINES DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 287 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 288 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 289 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 290 REST OF ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 291 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 292 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 293 SOUTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 294 SOUTH AMERICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 295 SOUTH AMERICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 296 SOUTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 297 SOUTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 298 SOUTH AMERICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 299 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 300 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 301 BRAZIL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 302 BRAZIL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 303 BRAZIL STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 304 BRAZIL ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 305 BRAZIL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 306 BRAZIL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 307 BRAZIL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 308 BRAZIL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 309 BRAZIL PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 310 BRAZIL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 311 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 312 ARGENTINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 313 ARGENTINA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 314 ARGENTINA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 315 ARGENTINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 316 ARGENTINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 317 ARGENTINA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 318 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 319 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 320 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 321 REST OF SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 322 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 323 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 324 MIDDLE EAST AND AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 325 MIDDLE EAST AND AFRICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 326 MIDDLE EAST AND AFRICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 327 MIDDLE EAST AND AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 328 MIDDLE EAST AND AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 329 MIDDLE EAST AND AFRICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 330 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 331 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 332 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 333 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 334 SAUDI ARABIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 335 SAUDI ARABIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 336 SAUDI ARABIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 337 SAUDI ARABIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 338 SAUDI ARABIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 339 SAUDI ARABIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 340 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 341 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 342 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 343 EGYPT PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 344 EGYPT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 345 EGYPT STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 346 EGYPT ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 347 EGYPT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 348 EGYPT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 349 EGYPT DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 350 EGYPT PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 351 EGYPT PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 352 EGYPT PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 353 U.A.E. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 354 U.A.E. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 355 U.A.E. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 356 U.A.E. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 357 U.A.E. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 358 U.A.E. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 359 U.A.E. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 360 U.A.E. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 361 U.A.E. PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 362 U.A.E. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 363 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 364 SOUTH AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 365 SOUTH AFRICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 366 SOUTH AFRICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 367 SOUTH AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 368 SOUTH AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 369 SOUTH AFRICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 370 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 371 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 372 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 373 ISRAEL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
TABLE 374 ISRAEL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 375 ISRAEL STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 376 ISRAEL ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 377 ISRAEL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 378 ISRAEL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 379 ISRAEL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 380 ISRAEL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)
TABLE 381 ISRAEL PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 382 ISRAEL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 383 REST OF MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 GLOBAL PEMPHIGUS VULGARIS MARKET: SEGMENTATION
FIGURE 2 GLOBAL PEMPHIGUS VULGARIS MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL PEMPHIGUS VULGARIS MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL PEMPHIGUS VULGARIS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL PEMPHIGUS VULGARIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL PEMPHIGUS VULGARIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL PEMPHIGUS VULGARIS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 GLOBAL PEMPHIGUS VULGARIS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL PEMPHIGUS VULGARIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL PEMPHIGUS VULGARIS MARKET: SEGMENTATION
FIGURE 11 THE EMERGING TREATMENT OPTIONS FOR THE PEMPHIGUS VULGARISIS EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL PEMPHIGUS VULGARIS MARKET FROM 2023 TO 2030
FIGURE 12 THE DIAGNOSIS AND TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL PEMPHIGUS VULGARIS MARKET IN 2023 AND 2030
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL PEMPHIGUS VULGARIS MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR PEMPHIGUS VULGARIS MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 15 PATIENT FLOW DESCRIPTION OF PEMPHIGUS VULGARIS:-
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL PEMPHIGUS VULGARIS MARKET
FIGURE 17 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2022
FIGURE 18 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2023-2030 (USD MILLION)
FIGURE 19 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, CAGR (2023-2030)
FIGURE 20 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, LIFELINE CURVE
FIGURE 21 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2022
FIGURE 22 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2023-2030 (USD MILLION)
FIGURE 23 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, CAGR (2023-2030)
FIGURE 24 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 25 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, 2022
FIGURE 26 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 27 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 28 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 29 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 30 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 31 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 32 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 33 GLOBAL PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022)
FIGURE 34 GLOBAL PEMPHIGUS VULGARIS MARKET: BY REGION (2022)
FIGURE 35 GLOBAL PEMPHIGUS VULGARIS MARKET: BY REGION (2023 & 2030)
FIGURE 36 GLOBAL PEMPHIGUS VULGARIS MARKET: BY REGION (2022 & 2030)
FIGURE 37 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT (2023 & 2030)
FIGURE 38 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022)
FIGURE 39 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022)
FIGURE 40 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 41 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 42 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT (2023-2030)
FIGURE 43 EUROPE PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022)
FIGURE 44 EUROPE PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022)
FIGURE 45 EUROPE PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 46 EUROPE PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 47 EUROPE PEMPHIGUS VULGARIS MARKET: DIAGNOSIS AND TREATMENT (2023-2030)
FIGURE 48 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022)
FIGURE 49 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022)
FIGURE 50 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 51 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 52 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: DIAGNOSIS AND TREATMENT (2023-2030)
FIGURE 53 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022)
FIGURE 54 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022)
FIGURE 55 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 56 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 57 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET: DIAGNOSIS AND TREATMENT (2023-2030)
FIGURE 58 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022)
FIGURE 59 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022)
FIGURE 60 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 61 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 62 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: DIAGNOSIS AND TREATMENT (2023-2030)
FIGURE 63 GLOBAL PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%)
FIGURE 64 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%)
FIGURE 65 EUROPE PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%)
FIGURE 66 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
